Scripps Research receives $50 million to advance therapies for tuberculosis, malaria and other global health challenges
January 29, 2020
LA JOLLA, CA – Scientists at Scripps Research’s drug development division, Calibr, have been awarded $50 million from the Bill & Melinda Gates Foundation to deliver new preclinical candidates against the global threats of tuberculosis and malaria, as well as to support research into pandemic preparedness, vaccine development, new contraceptives and gut health programs.
The funding will also boost Calibr’s continued efforts to repurpose existing drugs through the groundbreaking ReFRAME initiative. The five-year award is a renewal of the Calibr flagship portfolio grant and brings the total commitment from the Bill & Melinda Gates Foundation to $135 million between 2014 to 2024.
“Support from the Bill & Melinda Gates Foundation has allowed us to discover and advance several promising therapeutic candidates,” says Peter Schultz, PhD, chief executive officer of Calibr and Scripps Research. “The foundation’s continued generous support will tremendously accelerate our efforts to address unmet medical needs for millions of people around the globe.”
Since its founding by Schultz in 2012, Calibr has advanced Scripps Research technologies and become a leader in non-profit translational research. Between 2014 and 2019, Gates Foundation support for Calibr fueled major drug development breakthroughs and helped establish a team of more than 30 staff members and a network of partners focused on leveraging Calibr’s drug discovery expertise and infrastructure to tackle global health problems.
With Gates Foundation support, Calibr launched ReFRAME, a best-in-class resource focused on discovering ways to repurpose existing drugs to target diseases such as HIV, tuberculosis and parasites that cause severe illnesses in children.
Calibr has generated five preclinical candidates against malaria, HIV and parasites and several additional preclinical candidate opportunities.
Calibr-Skaggs advances CLF065, a regenerative GLP-2 therapy, into two Phase 2 IBD studies
CLF065, a long-acting, once-weekly GLP-2 receptor agonist, advances in two inflammatory bowel disease indications. The studies aim to bring a regenerative treatment option to patients living with IBD, who currently have few therapies that repair the damaged intestinal lining at the root of their disease.
What’s next for IBD care: Insights from a surgeon-scientist
The data is clear: inflammatory bowel diseases like ulcerative colitis and Crohn’s are on the rise worldwide. In this episode, we sit down with Dr. Amy Lightner—VP of Clinical Development at Calibr-Skaggs and colorectal surgeon at Scripps Clinic—to explore what drives these diseases, an upcoming phase 2 clinical trial for a new regenerative medicine, and how she balances life between the operating room and the research lab.
Reprogramming the immune system: Precision immunotherapy for cancer and autoimmune disease
Your immune system is your body’s natural defense, capable of identifying what belongs and what doesn’t. But when it falters, it can let cancer grow unchecked or mistakenly attack your own healthy tissues, leading to autoimmune diseases. What if we could reprogram the immune system to tip the balance in our favor, gaining an advantage over both cancers and autoimmune disorders? In this Front Row lecture, Calibr-Skaggs’ vice president of biologics, Travis Young, shared how Scripps Research is using genetic engineering to reprogram patients’ own immune cells to create personalized “switchable” CAR-T cell therapies. This approach represents a new class of precision immunotherapy designed to induce deep and durable remissions in patients with a wide range of cancers, from lymphoma to breast cancer, as well as in chronic autoimmune conditions such as lupus, rheumatoid arthritis and systemic sclerosis. Young explained how this breakthrough strategy works and what it could mean for the future of medicine.
Viome and Scripps Research partner to develop first at-home RNA screening test to prevent colon cancer before it strikes
First-of-its-kind 1,000-patient clinical study will use RNA-based stool and saliva tests to detect colon polyps — early warning signs of colorectal cancer — before they become cancerous.Study aims to enhance colorectal cancer prevention by identifying polyp molecular signals, offering improved sensitivity over at-home DNA tests, which have limited ability to detect precancerous lesions.